Table 1. Clinical and Biological Characteristics of patients at diagnosis according to transcript subtype (e13a2 versus e14a2) (n = 114).
| Characteristic | N = (%) or median [range] | ||
|---|---|---|---|
| e14a2 | e13a2 | p = | |
| N | 63 (55.3) | 51 (44.7) | |
| Gender, male | 33 (52.4) | 27 (52.9) | .95 |
| Age (years) | 49 [19–84] | 53 [18–78] | .27 |
| Hemoglobin (g/L) | 118 [69–157] | 114 [79–156] | .48 |
| WBC count (103/μL) | 106 [4.5–623] | 156 [17.6–552.5] | .17 |
| PLT count (103/μL) | 405 [83–1999] | 311 [104–1315] | .14 |
| Peripheral blasts (%) | 1.0 [0–13] | 1.1 [0–7] | .98 |
| ELTS score | |||
| Low | 32 (52.5) | 24 (48) | .87 |
| Intermediate | 21 (34.4) | 18 (36) | |
| High | 8 (13.1) | 8 (16) | |
| EUTOS score | |||
| Low | 55 (90.2) | 45 (90) | .98 |
| High | 6 (9.8) | 5 (10) | |
| Sokal score | |||
| Low | 21 (34.4) | 16 (32) | .84 |
| Intermediate | 27 (44.3) | 21 (42) | |
| High | 13 (21.3) | 13 (26) | |
| Hasford score | |||
| Low | 24 (39.3) | 13 (26) | .08 |
| Intermediate | 25 (41) | 31 (62) | |
| High | 12 (19.7) | 6 (12) | |
| ACA Ph+ or variant translocation | 8 (13.1) | 10 (20) | .35 |
| Median duration of treatment (months) | 42 [3–111] | 49 [2–104] | .47 |
| Median follow-up (months) | 46 [3–121] | 53 [3–111] | .97 |
Abbreviations: ACA Ph+, additional chromosome abnormalities in Ph+ cells; EUTOS, European Treatment and Outcome Study; ELTS, EUTOS long-term survival; PLT, platelets; WBC, white blood cells.